Nasdaq
$4.00▼ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $501.2MShares out 1.300M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 1d agoRegular26.10.24 02:384Ownership#●●●
Aquestive Therapeutics, Inc.
Aquestive Therapeutics insider John Cochran filed a Form 4 report on October 23, 2026, disclosing changes in beneficial ownership of securities effective as of October 21, 2026.…more
$4.00-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 05:048-KKey event
Aquestive Therapeutics, Inc.
Aquestive Therapeutics amended its bylaws on October 15, 2026. The amendment eliminates the requirement for nominating stockholders to provide information regarding relationships between the nominating stockholder and the proposed nominee, as well as persons acting in concert with them.…more
$4.00-0.12%vs prev closeView filingShare - 10.16Regular26.10.17 03:174Ownership
Aquestive Therapeutics, Inc.
Insider Daniel Barber of Aquestive Therapeutics reported a change in beneficial ownership of securities on October 15, 2026. This filing is a standard Form 4 disclosure regarding changes in executive shareholdings.…more
$4.00-0.12%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.15Pre-market26.10.15 20:00#●●●#●●●
Aquestive Therapeutics Receives FDA Acceptance for Anaphylm NDA Resubmission…more
Aquestive Therapeutics announced that the FDA has accepted the resubmission of its New Drug Application for Anaphylm, an oral treatment for severe allergic reactions. The FDA has set a PDUFA goal date of March 16, 2027, for a final decision on the application.…more
$4.00-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Regular26.10.15 02:34
●●●●●●●● ●●●●● ●●●●●●
Eton Pharmaceuticals has entered into an exclusive licensing agreement for the U.S. commercialization of Aquestive Therapeutics' seizure cluster treatment, LIBERVANT. The company plans to launch the product in April 2027, marking its strategic expansion into the neurology market.…more
$4.00-0.12%vs prev closeShareBenzinga - 9.17Regular26.09.18 00:40
●●●●●●●● ●●●●● ●●●●●●
Aquestive Therapeutics has officially resubmitted its New Drug Application to the FDA for its sublingual allergy treatment, Anaphylm. The company completed the requested pharmacokinetic and human factors studies to address previous regulatory concerns.…more
$4.00-0.12%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report